Lung Cancer

The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the role of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

Stephen Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

Julie R. Brahmer, MD, discusses updates on the use of immunotherapy in patients with metastatic non–small cell lung cancer.

Within the last decade, 4 tyrosine kinase inhibitors have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer.

Tumor mutational burden has been shown in studies to predict response to immunotherapies in certain types of cancer and is being validated in clinical trials as a biomarker of response.

Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

Deepa S. Subramaniam, MBBS, MSc, discusses the complex and evolving treatment paradigm of BRAF- and ROS1-driven non–small cell lung cancer.

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to targeted therapies in oncogene-driven non–small cell lung cancer.

The European Commission has approved brigatinib (Alunbrig) for the treatment of adult patients with ALK-positive non–small cell lung cancer who were previously treated with crizotinib (Xalkori).

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did not improve overall survival versus placebo as a maintenance therapy for patients with extensive-stage small cell lung cancer without disease progression following frontline platinum-based chemotherapy.

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval larotrectinib in NTRK-positive cancers.

Thomas Hensing, MD, discusses the emergence of immunotherapy in the stage III non–small cell lung cancer armamentarium, and questions that must be answered to build on this initial success.

Charles M. Rudin, MD, PhD, reflects on the latest developments in small cell lung cancer.

Lawrence E. Feldman, MD, discusses exciting new data surrounding immunotherapy combinations in lung cancer.